1 / 12

Yakov Goldich, MD, 1 David Zadok, MD, 1 Arie L Marcovich, MD, 2

Riboflavin - UVA Collagen Crosslinking for Progressive Keratoconus: Two - Year Efficacy and Safety Results. Yakov Goldich, MD, 1 David Zadok, MD, 1 Arie L Marcovich, MD, 2 Ami Hirsh, MD, 3 Yaniv Barkana, MD, 1 Isaac Avni, MD 1

xarles
Télécharger la présentation

Yakov Goldich, MD, 1 David Zadok, MD, 1 Arie L Marcovich, MD, 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Riboflavin - UVA Collagen Crosslinking for Progressive Keratoconus: Two - Year Efficacy and Safety Results Yakov Goldich, MD,1 David Zadok, MD,1 Arie L Marcovich, MD,2 Ami Hirsh, MD,3 Yaniv Barkana, MD,1 Isaac Avni, MD1 1Department of Ophthalmology, Assaf Harofeh Medical Center, Israel 2Department of Ophthalmology, Kaplan Medical Center, Israel 3Enaim Refractive Surgery Centers, Israel The authors have no conflicts of interest and no financial interest in the article’s subject matter or methods mentioned.

  2. Methods • This was a prospective clinical controlled study. • Fourteen eyes of 14 patients with progressive keratoconus were treated with Corneal collagen crosslinking using Ultraviolet-A light and Riboflavin following corneal deepithelization. • Patients were assessed preoperatively, at week 1, month 1, 3, 6, 9, 12 and 24 after treatment. • We measured UCVA & BCVA (logMAR), refraction, biomicroscopy and fundus examination, IOP, endothelial cell density (ECD), corneal topography, minimal corneal thickness (MCT), macular OCT, and corneal biomechanics with the ocular response analyzer. • Inclusion criteria • Progressive ectasia documented clinically within the past 12 months • Age >18 years • Absence of corneal opacities • Minimum corneal thickness > 400 μm • CLW stopped 1 month before initial evaluation • One eye treated

  3. Results: Best Corrected Distance Visual Acuity with Glasses logMAR 0.21  logMAR 0.14, P = 0.018

  4. Results: Uncorrected Distance Visual Acuity logMAR0.63  logMAR0.82, P = 0.47

  5. Results: Spherical Equivalent -5.3 D  -4.0 D, P = 0.017

  6. Results: K max 54.0 D  51.68 D P = 0.003

  7. Results: K cyl (K max – K min) 10.3 D  8.1 D P = 0.01

  8. Results: Corneal Hysteresis 8.24 mmHg  7.34 mmHg, P = 0.15

  9. Results: Corneal Resistance Factor 7.0 mmHg  6.58 mmHg, P = 0.9

  10. Results: Endothelial Cell Density 2730 cells/mm2 2541 cells/mm2 P = 0.2

  11. Other Results • No statistically significant changes of: • Minimal corneal thickness • Goldmann applanation IOP • Goldmann-correlated IOP • Corneal-compensated IOP • Central foveal thickness • We noted prolonged mild corneal haze in 2 patients, with complete resolution in one patient after 9 months.

  12. Conclusions • Two years results following UVA-Riboflavin CXL show stable visual acuity, stable corneal thickness, and significant decrease in keratometry. • The underlying biomechanical processes that take place in the corneal stroma following CXL remain unclear. • It appears to be a safe procedure that does not cause damage to the corneal endothelium and central retina. • The longer-term effect and safety of this procedure require further study. Correspondence: Yakov Goldich MD,E-mail: doctor.goldich@gmail.com

More Related